(PharmaNewsWire.Com, May 15, 2017 ) According to Publisher, the Global Auto Injectors Market is accounted for $1.10 billion in 2015 and is expected to reach $3.78 billion by 2022 growing at a CAGR of 19.42%. As large number of patients are opting for self administered treatment and care there is a flawless increase in use of Auto Injectors. Moreover, the high prevailing patients of anaphylaxis had presented a huge demand for the market which seems as pertaining factor behind the market growth. At the same time high cost and need for utmost care are some of the factors hampering the market.
Some of the major key players of the market are Unilife Corporation, Novartis International AG, Becton, Dickinson and Company, Antares Pharma, Inc., Mylan, Inc., Adamis Pharmaceuticals Corp, Hospira Inc, Scandinavian Health Limited (SHL) Group, Sanofi SA, Itelliject Inc , Pfizer, Inc., Lincoln Medical Ltd, Ypsomed Holdings AG, ALK Abello, Teva Pharmaceuticals Ltd and Biogen Idec, Inc.
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific - Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
